Works matching IS 15257304 AND DT 2022 AND VI 23 AND IP 8

Results: 9

Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 694, doi. 10.1016/j.cllc.2022.09.003

By:

Banks, Kian C.;
Ossowski, Stephanie;
Yun-Yi Hung;
Hsu, Diana S.;
Ashiku, Simon K.;
Patel, Ashish R.;
Velorta, Jeffrey B.;
Suga, J. Marie

Publication type:

Article

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 670, doi. 10.1016/j.cllc.2022.07.012

By:

Myung-Ju Ahn;
Mendoza, Marvin Jonne L.;
Pavlakis, Nick;
Terufumi Kato;
Soo, Ross A.;
Dong-Wan Kim;
Chong Kin Liam;
Te-Chun Hsia;
Chee Khoon Lee;
Thanyanan Reungwetwattana;
Sarayut Geater;
Siu Hong Chan, Oscar;
Naiyarat Prasongsook;
Solomon, Benjamin J.;
Thi Thai Hoa Nguyen;
Toshiyuki Kozuki;
Chih-Hsin Yang, James;
Yi-Long Wu;
Shu Kam Mok, Tony;
Shao-Weng Tan, Daniel

Publication type:

Article

Association Between Survival and Very High Versus High PD-L 1 Exp ression in Patients Receiving Pembronzumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 731, doi. 10.1016/j.cllc.2022.07.003

By:

Shah, Mohsin;
Marmarelis, Melina E.;
Mamtani, Ronac;
Hennessy, Sean

Publication type:

Article

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 709, doi. 10.1016/j.cllc.2022.07.009

By:

Li Zhou;
Yanjuan Xiong;
Yang Wang;
Yuan Meng;
Weihong Zhang;
Meng Shen;
Xinwei Zhang;
Shuzhan Li;
Baozhu Ren;
Runmei Li;
Ying Han;
Jiali Zhang;
Shui Cao;
Weijiao Du;
Qian Sun;
Feng Wei;
Xiumei An;
Lili Yang;
Yuwei Zhang;
Wenchao Ma

Publication type:

Article

Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 686, doi. 10.1016/j.cllc.2022.07.015

By:

Mengni Guo;
VanderWalde, Ari M.;
Xinhua Yu;
Vidal, Gregory A.;
Tian, G. Gary

Publication type:

Article

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 720, doi. 10.1016/j.cllc.2022.07.008

By:

Myung J. Ahn;
Hye R. Kim;
Yang, James C. H.;
Ji-Yu Han;
Yu-Chung. Li, Jacky;
Hochmair, Maximilian J.;
Gee-Chen Chang;
Delmonte, Angelo;
Ki H. Lee;
Campelo, Rosario G.;
Gridelli, Cesare;
Spira, Alexander I.;
Califano, Raffaele;
Griesinger, Frank;
Ghosh, Sharmistha;
Felip, Enriqueta;
Dong-Wan Kim;
Yuyin Liu;
Pingkuan Zhang;
Popat, Sanjay

Publication type:

Article

Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 659, doi. 10.1016/j.cllc.2022.09.008

By:

Yuting Kuang;
Singh, Rajpal;
Nevo, Arianna;
Deitz, Anne C.;
Pietanza, M. Catherine;
Aixue Liu;
Uyei, Jennifer;
Ke Zu

Publication type:

Article

A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 702, doi. 10.1016/j.cllc.2022.07.016

By:

Itchins, Malinda;
Ainsworth, Hannah;
Alexander, Marliese;
Dean, Samantha;
Dharmaraj, Devi;
Pavlakis, Nick;
Clarke, Stephen J.;
Brown, Chris;
Torres, Javier;
Saqib, Ayesha;
Ladwa, Rahul;
O'Byrne, Kenneth;
Moore, Melissa;
Po Yee Yip;
Solomon, Ben;
John, Tom;
Kao, Steven;
Mitchell, Paul;
Parakh, Sagun

Publication type:

Article

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 8, p. 643, doi. 10.1016/j.cllc.2022.08.009

By:

Leal, Jose Luis;
John, Thomas

Publication type:

Article